Around 1 in 10 babies are in need of some form of stabilisation at birth.
The heart rate of the baby is critical for guiding the stabilisation or resuscitation process; however, current monitoring methods do not always provide an early enough or sometimes an accurate enough heart rate which can lead to inappropriate clinical interventions (Voogdt). Adherence to guidelines is sub-optimal (Mann, Cusack) which impacts on babies’ welfare, their families, and healthcare resources.
SurePulse VS represents a significant innovative and baby-centric step forwards in addressing the clinical need for accurate, wireless neonatal heart rate monitoring.
The correct care of the newborn baby in the first few ‘golden’ minutes after birth is critical to prevent significant illness or even death. A rise in heart rate is the most important indicator of effective ventilation and response to resuscitation interventions (Aziz). Establishing a timely and accurate heart rate and monitoring it through stabilisation (and resuscitation where needed) supports optimal clinical decision making. However, current heart rate assessment is often not quick enough, is cumbersome, or underestimates heart rate leading to overtreatment, representing ongoing neonatal clinical challenges (Dawson, Bajaj).
Receiving the right information at the right time is essential for adherence to guidelines, yet ‘guideline errors’ exist and there is significant variation from gold-standard protocols such as the Newborn Life Support Guidelines in the UK (Cusack, Duran).
Delayed resuscitation can have significant consequences. In 2017 there were 1,267 neonatal deaths in the UK, 68% of them between birth and 7 days, 119 of them were from cardio-respiratory causes (MBRRACE 2019).
Training, teamwork, and access to timely accurate information remain opportunities that SurePulse VS can help address. The clinical need for accurate, wireless neonatal heart rate monitoring is evident.
SurePulse VS addresses many of the neonatal clinical challenges associated with current approaches to heart rate assessment:
Whilst infrequent events, both Pulseless Electrical Activity (PEA) and Sudden Unexpected Postnatal Collapse (SUPC) continue as neonatal clinical challenges associated with poor outcomes for babies and their families. SurePulse VS with the cap-mounted wireless, continuous and real-time heart rate monitoring can support new advances in risk mitigation (HSIB, Luong).
“There were more wires than him” (Bonner)
SurePulse VS opens possibilities to enhance family integrated care for newborn babies, as heart rate can be monitored wirelessly allowing more confident early bonding and breastfeeding opportunities.
In addition, the wireless heart rate monitoring and data/event recording features support several evolving delivery room practices including delayed cord clamping, quality improvement, perinatal MDT teamwork, and less-invasive approaches to stabilisation/resuscitation.
Source: Five years of cerebral palsy claims – A thematic review of NHS Resolution data.
Source: Five years of cerebral palsy claims – A thematic review of NHS Resolution data.
If you want to learn how SurePulse VS may help mitigate neonatal risks and enhance family integrated care, please contact us.